CompletedPHASE1, PHASE2NCT03812263

A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Studying Leukocyte adhesion deficiency

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Rocket Pharmaceuticals Inc.
Principal Investigator: Donald B Kohn, MD, D.D.S
University of California, Los Angeles
Intervention: RP-L201(biological)
Enrollment: 9 enrolled
Eligibility: All sexes
Timeline: 2019 – 2023

Study locations (3)

University of California, Los Angeles, Los Angeles, California, United States
Hospital Infantil Universitario Niño Jesús (HIUNJ), Madrid, Spain
University College London Great Ormond Street Institute of Child Health, London, United Kingdom

Collaborators

California Institute for Regenerative Medicine (CIRM)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03812263 on ClinicalTrials.gov

Other trials for Leukocyte adhesion deficiency

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGNCT06282432
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals Inc.

See all trials for Leukocyte adhesion deficiency →

← Back to all trials